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  The eflicacy ofprostate specific antigen density （PSAD） in diagnosing prostate cancer was assessed
in 98 patients with serum prostate specific antigen （PSA） ievels between 2 and 10 ng／mi who had a
pathological diagnosis made by prostate biopsy or transurethral resection of the prostate．
  Of the 98 patients， 22 （2／20／o） had prostate cancer． The PSA （based on a cut－off value of 4．5
ng／ml） had a sensitivity and po”s’itive predictive value （PPV） of 820／o and 380／o， respectively， for
diagnosing prostate cancer， while the results for PSAD （based on a cut－offvalue ofO．13） were 91 O／o and
610／o． The PSAD was more eflicient than the PSA levels and was also superior to digital rectal
examination （DRE） combined with transrectal ultrasonography （TRUS）， for which the sensitivity and
PPV were 730／o and 390／o， respectively．
  Six （110／o） out of 57 patients who were normal on DRE and TRUS had pros，tate cancer． ln these
57 patients， the PSA （cut－off value ： 4．5 ng／ml） had a sensitivity of 500／o and PPV while the values for
PSAD （cut－off value ： O．13） were 830／o and 360／o respectively． The PSAD could effectively detect even
impalpable prostate cancer not visible on TRUS．
                                （Acta Urol． Jpn． 43： 13－18， 1997）



































































Table 1． Modes of biopsy and pathological
     diagnosis




































癌症例の臨床病期の内訳はA22例， Bo 4例， B 13
例，B21例，Cll例，D21例であった．
2．PSA， PSAD，直腸診およびTRUSの診断能
 （Table 3， 4）
 PSA， PSAD cut off値の設定は江藤らの方法に準
じ，PSAではcut off値をO．5 ng／mlおきに， PSAD
では0．05より0．01おきにefficiencyを求めた．その結








Table 2． Patients with gray zone level of PSA （2．0－9．9 ng／ml） （n＝98）




























木原，ほか：前立腺癌・PSA density・Gray zone 15
Table 3． Diagnostic efficacy of different examinations （n ＝98）































































Table 4． Comparison of diagnosis of different examination （n＝98）
Prostate cancer Not prostate cancer




































































Table 5． Comparison of diagnosis of PSA and
     PSAD in patients with normal findings
     on DRE and／or TRUS （n＝57） ：
Prostate cancer Not prostate cancer
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Table 6．Comparison of the diagnostic efficacy of PSA and PSAD in patients
with normal findings on DRE and／or TRUS （n＝57） ：
Sensitivity Specificity PPV NPV Eraciency （％）
PSA cut－off value 4．5 ng／ml





































































































BPHとの鑑別能を高めるため， age specific refe－























対してもPSADはsensitivity 83％， specificity 82％，
PPV 36％， NPV 98％と高い癌検出力を認めた．
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